Myocardial protective effects of rosuvastatin in patients with unstable angina pectoris undergoing coronary stent implantation / 药物评价研究

ABSTRACT

Objective To investigate the myocardial protective effects of rosuvastatin in patients with unstable angina pectoris undergoing coronary stent implantation.Methods Patients (90 cases) with unstable angina pectoris undergoing coronary stent implantation in No.215 Hospital of Shanxi Nuclear Industry from January 2014 to May 2016 were divided into observation group and control group,45 cases in each group.Patients in the observation group were treated with rosuvastatin,and patients in the control group were treated with atorvastatin.The levels of CK-MB,cTnⅠ,h-FABP,hs-CRP,TNF-α,INF-γ,IL-6,IL-10,and IL-18 were compared between two groups.Adverse drug reaction and major adverse cardiac events of two groups were recorded.Results After 24 h operation,the levels of CK-MB,cTnⅠ,hs-CRP,TNF-α,INF-γ,IL-10,and IL-18 of two group were significantly higher than those before operation (P ＜ 0.05),and those in observation group were significantly lower than control group (P ＜ 0.05).There was no difference in h-FABP between two groups before and after operation (P ＜ 0.05).The level of IL-6 in the observation group after operation was higher than that before operation,but the difference was not significant (P ＜ 0.05);The level of IL-6 in the control group was significantly higher than that before operation and that of observation group (P ＜0.05);The rates of drug adverse reactions and major adverse cardiac events were similar in two groups.Conclusion Compared with same doseatorvastatin,the effects of rosuvastatin in muscle damage and inflammatory response are better,and do not increase adverse reactions.